ATE480534T1 - Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz - Google Patents

Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz

Info

Publication number
ATE480534T1
ATE480534T1 AT05772857T AT05772857T ATE480534T1 AT E480534 T1 ATE480534 T1 AT E480534T1 AT 05772857 T AT05772857 T AT 05772857T AT 05772857 T AT05772857 T AT 05772857T AT E480534 T1 ATE480534 T1 AT E480534T1
Authority
AT
Austria
Prior art keywords
yloxy
methylpropyl
phenoxy
amino
pyridinecarbonic
Prior art date
Application number
AT05772857T
Other languages
English (en)
Inventor
Julie Bush
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE480534T1 publication Critical patent/ATE480534T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05772857T 2004-07-22 2005-07-14 Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz ATE480534T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59025104P 2004-07-22 2004-07-22
PCT/US2005/024886 WO2006019835A1 (en) 2004-07-22 2005-07-14 A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinicarbox amide hemisuccinate salt

Publications (1)

Publication Number Publication Date
ATE480534T1 true ATE480534T1 (de) 2010-09-15

Family

ID=35106749

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05772857T ATE480534T1 (de) 2004-07-22 2005-07-14 Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz

Country Status (17)

Country Link
US (1) US7834187B2 (de)
EP (2) EP1773811B1 (de)
JP (1) JP4922163B2 (de)
CN (1) CN1989129B (de)
AT (1) ATE480534T1 (de)
AU (1) AU2005275185B2 (de)
BR (1) BRPI0513569A2 (de)
CA (1) CA2572631C (de)
CY (1) CY1110806T1 (de)
DE (1) DE602005023474D1 (de)
DK (1) DK1773811T3 (de)
ES (1) ES2349798T3 (de)
MX (1) MX2007000892A (de)
PL (1) PL1773811T3 (de)
PT (1) PT1773811E (de)
SI (1) SI1773811T1 (de)
WO (1) WO2006019835A1 (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235919A (en) * 1977-07-21 1980-11-25 Sandoz Ltd. 1-(Indol-4-yloxy)-3-(2-substituted amino)-2-propanols and pharmaceutical use thereof
EP0827746B1 (de) * 1996-09-05 2002-04-03 Eli Lilly And Company Carbazolanaloge als selektive beta3-adrenergische Agonisten
DE60005693T2 (de) * 1999-07-29 2004-07-29 Eli Lilly And Co., Indianapolis Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid
WO2001009116A2 (en) * 1999-07-29 2001-02-08 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE
US20040014672A1 (en) * 2000-10-20 2004-01-22 Luke Wayne Douglas Novel crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
EP2332934B1 (de) * 2001-08-15 2017-03-01 Pharmacia & Upjohn Company LLC Verfahren zur herstellung von kristallen enthaltend ein malatsalz von n-[2-(diethylamino)ethyl]-5-[(5-fluor-1,2-dihydro-2-oxo-3h-indol-3-yliden)methyl]-2,4-dimethyl-1h-pyrrol-3-carboxamid.

Also Published As

Publication number Publication date
DE602005023474D1 (en) 2010-10-21
CA2572631A1 (en) 2006-02-23
PL1773811T3 (pl) 2011-02-28
AU2005275185A1 (en) 2006-02-23
EP1773811A1 (de) 2007-04-18
US20080058385A1 (en) 2008-03-06
MX2007000892A (es) 2007-05-23
PT1773811E (pt) 2010-10-19
DK1773811T3 (da) 2010-12-13
AU2005275185B2 (en) 2011-06-23
CY1110806T1 (el) 2015-06-10
BRPI0513569A2 (pt) 2012-10-09
WO2006019835A1 (en) 2006-02-23
JP2008507519A (ja) 2008-03-13
SI1773811T1 (sl) 2011-01-31
EP2233482A1 (de) 2010-09-29
EP1773811B1 (de) 2010-09-08
CA2572631C (en) 2012-05-15
CN1989129B (zh) 2010-11-10
US7834187B2 (en) 2010-11-16
ES2349798T3 (es) 2011-01-11
CN1989129A (zh) 2007-06-27
JP4922163B2 (ja) 2012-04-25

Similar Documents

Publication Publication Date Title
PE20060243A1 (es) Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina
CA2401241A1 (en) 2-amino-3-(alkyl)-pyrimidone derivatives as gsk3.beta. inhibitors
DE60140581D1 (de) Pharmazeutische Zusammensetzungen beinhaltend Kristallsalze von 7-Ä4-(4-Fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ-(3R,5S)-3,5-dihydroxyhept-6-ensäure
EP2578574A4 (de) Optisch aktives dibenzylaminderivat und herstellungsverfahren dafür
RU2009149216A (ru) Бициклические амиды как ингибиторы киназы
DK1533304T3 (da) Amidderivat
NO20061420L (no) 3-[(2-{4-Heksyloksykarbonylamino-Imino-metyl)-Fenylamino]-Metyl}-1-Metyl-1H-Benzimidazol-5-Karbonyl)-Pyridin-2-yl-Amino]-Propansyre Etylester Metansulfonat og
ATE551059T1 (de) Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
EA199800912A1 (ru) Дигидратная соль мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2(1н)-индол-2-она, фармацевтическая композиция и способ лечения психотического расстройства
DE60012751D1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
MA28428B1 (fr) FORMES SALINES DE 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO) PHENYL]-BENZAMIDE
PE20100093A1 (es) Derivados de acetileno
ATE251142T1 (de) Eine kristallmodifikation von celecoxib
TWI318624B (en) Process for the preparation of a 2-ethylaminopyridine derivative
DK1599455T3 (da) 4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose
ATE480534T1 (de) Kristallines variables hydrat von (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxy ropyl)amino)-2- methylpropyl)phenoxy)-3-pyridincarbonsäureamid- hemisuccinatsalz
ATE256678T1 (de) 4-(2-pyridyl)piperazine als agonisten des 5ht7 rezeptors
UA92354C2 (en) Amino acid salts of rosiglitazone
BR0314461A (pt) Processo para a preparação de derivado de 2-aminometilpiridina
DK1174131T3 (da) Anvendelse af et middel til forbedring af astrocytfunktion til behandling af Parkinsons sygdom
DK1565441T3 (da) Fremgangsmåde til fremstilling af 2-aminomethylpyridinderivater
NO20055883L (no) Fremgangsmate for fremstilling av racemisk 2-{[2-(4-hydroksfenyl)etyl]tio}-3-[4-(2-{4-[(metylsulfonyl)oksy]fenoksy}etyl)fenyl]-propansyre
BR0104344A (pt) Análagos de fenoxazina úteis como inibidores de agregação amilóide e tratamento da doença de alzheimer e de disfunções relacionadas com a amiloidose
TH61102A (th) รูปเกลือของ e-2-เมธอกซิ-n-(3-{4- [3-เมธิล-4-(6-เมธิล-พิริดิน-3-อิลออกซิ) -เฟนิลอะมิโน] -ควินาโนโซลิน-6-อิล}-แอลลิล) -แอซิทาไมด์ และวิธีการผลิต
WO2007000392A3 (en) Chloro-substituted guanidines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1773811

Country of ref document: EP